XEN496

DRUG2 trials

Sponsors

Xenon Pharmaceuticals Inc.

Conditions

Brain DiseasesCentral Nervous System DiseasesDiseaseEpilepsyEpilepsy in ChildrenEpilepsy; SeizureEpileptic SyndromesNervous System Diseases

Phase 3

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

TerminatedNCT04639310

Xenon Pharmaceuticals Inc.Brain Diseases, Central Nervous System Diseases, Disease +5

Start: 2021-03-29End: 2023-05-16Updated: 2024-08-23

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

TerminatedNCT04912856

Xenon Pharmaceuticals Inc.Brain Diseases, Central Nervous System Diseases, Disease +5

Start: 2021-08-17End: 2023-11-17Updated: 2025-02-14